Role of osteoprotegerin (OPG) in cancer
- 10 February 2006
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 110 (3) , 279-291
- https://doi.org/10.1042/cs20050175
Abstract
OPG (osteoprotegerin), a secreted member of the TNF (tumour necrosis factor) receptor superfamily, has a variety of biological functions which include the regulation of bone turnover. OPG is a potent inhibitor of osteoclastic bone resorption and has been investigated as a potential therapeutic for the treatment of both osteoporosis and tumour-induced bone disease. Indeed, in murine models of cancer-induced bone disease, inhibition of osteoclastic activity by OPG was also associated with a reduction in tumour burden. The discovery that OPG can bind to and inhibit the activity of TRAIL (TNF-related apoptosis-inducing ligand) triggered extensive research into the potential role of OPG in the regulation of tumour cell survival. A number of reports from studies using in vitro models have shown that OPG protects tumour cells from the effects of TRAIL, thereby possibly providing tumour cells that produce OPG with a survival advantage. However, the ability of OPG to act as a tumour cell survival factor remains to be verified using appropriate in vivo systems. A third area of interest has been the use of OPG as a prognostic marker in various cancer types, including myeloma, breast and prostate cancer. This review provides an overview of the role of OPG in cancer, both in cancer-induced bone disease and in tumour growth and survivalKeywords
This publication has 57 references indexed in Scilit:
- Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?Breast Cancer Research and Treatment, 2005
- Osteoprotegerin in Prostate Cancer Bone MetastasisCancer Research, 2005
- Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinomaCancer, 2004
- Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myelomaLeukemia, 2004
- Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancerThe Prostate, 2004
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood, 2002
- A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and functionBiochemical and Biophysical Research Communications, 2002
- Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentThe Journal of Experimental Medicine, 2002
- Proposed Standard Nomenclature for New Tumor Necrosis Factor Family Members Involved in the Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory FactorPublished by Elsevier ,1998